Altamira Therapeutics .(CYTO) GlobeNewswire News Room·2024-08-26 14:41Core Insights - Altamira Therapeutics Ltd. has made significant advancements in immune checkpoint inhibitor therapy using Zbtb46 mRNA delivered via SemaPhore nanoparticles, showing promising results in animal tumor models with a significant tumor size reduction (p<0.0001) [1] - The Zbtb46 gene plays a crucial role in modifying the tumor microenvironment, enhancing the effectiveness of anti-PD1 treatments and leading to improved outcomes in cancer patients [2] - Altamira Medica's Bentrio nasal spray has been confirmed free of WADA prohibited substances, making it safe for athletes and addressing allergy management without doping risks [2] - Preclinical data indicates that SOD2 mRNA delivered via SemaPhore nanoparticles significantly reduces abdominal aortic aneurysm progression and improves survival rates (p<0.01) [3][4] - Altamira Therapeutics is expanding the distribution of Bentrio to Sweden and Denmark following its successful launch in Norway, aiming to establish a strong presence in the Scandinavian market [5] Company Developments - Altamira Therapeutics focuses on RNA-based treatments for non-liver targets using its OligoPhore and SemaPhore delivery platforms, with ongoing preclinical projects targeting KRAS-driven cancer and rheumatoid arthritis [6] - The company is divesting or out-licensing its legacy assets in allergology, viral infection, and inner ear therapeutics to streamline its focus on core projects [6] Research and Collaboration - The research on Zbtb46 mRNA was conducted by the Pathology & Immunology Department of Washington University School of Medicine, indicating strong academic collaboration [1] - The study on SOD2 mRNA was a joint effort between Washington University in St. Louis and the University of South Florida, highlighting the collaborative nature of Altamira's research initiatives [3][4]